source
- Cellectis quits CAR-T and pivots to ‘in vivo’ gene editingLong a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.BioPharma Dive · 49m ago↗ source
- Summit, BioNTech, more headline WCLC with next-gen lung cancer drugsBioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…BioSpace · 1h ago↗ source
- Analysis says secret Trump pharma deals could cut projected Medicare savings from MFN pricing by up to 80%A new analysis warns that confidential agreements between the Trump administration and more than two dozen drug makers could dramatically shrink the savings expected from the "most‑favored‑nation"…